Kane Biotech (KNE) Price & Analysis

Compare

1 Followers

KNE Stock Chart & Stats

C$0.03

<C$0.01(4.76%)

At close: Jan 08 4:00 PM EST

C$0.03

<C$0.01(4.76%)

Day’s Range― - ―

52-Week RangeC$0.03 - C$0.12

Previous CloseN/A

Volume199.87K

Average Volume (3M)112.95K

Market Cap

C$7.26M

Enterprise ValueC$8.05M

Total Cash (Recent Filing)C$939.06K

Total Debt (Recent Filing)C$2.30M

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Mar 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding181,596,560

10 Day Avg. Volume120,057

30 Day Avg. Volume112,955

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)-9.04

Price to Sales (P/S)7.08

P/FCF Ratio-3.56

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Patented Antimicrobial TechnologyKane Biotech’s focus on patented antimicrobial and anti-biofilm technologies represents a durable competitive advantage. Patents and specialized science underpin barriers to entry, support pricing power in niche clinical, veterinary and industrial markets, and enable long-term licensing and product differentiation.

Diversified Revenue StreamsMultiple revenue channels—direct product sales, licensing/royalties, and partnership milestone potential—reduce single-market dependence. This diversification supports steadier cash inflows over time, allows risk sharing with partners, and creates recurring royalty revenue that can stabilize finances if product adoption grows.

Improving Free Cash Flow GrowthReported free cash flow growth of ~5.15% in the trailing period signals initial progress toward self-funded operations. If sustained, rising FCF can reduce the need for external financing, support R&D and commercialization, and materially improve long-term liquidity and operational resilience.

Bears Say

Severe Revenue DeclineA near 69% revenue drop is a structural red flag: it erodes economies of scale, weakens market positioning, and constrains reinvestment in R&D and commercialization. Sustained top-line contraction undermines the company’s ability to translate its IP and partnerships into durable, profitable growth.

Deep Negative ProfitabilityExtremely negative net and operating margins indicate persistent operating losses that are unlikely to be resolved without structural revenue recovery or cost realignment. Continued losses deplete capital, hinder strategic investment, and increase dependency on dilutive or expensive financing over the medium term.

Weak Balance Sheet And High LeverageNegative equity and an effective debt-to-equity of -11.09 reflect severe capitalization issues and high leverage, reducing financial flexibility. This raises refinancing risk, limits ability to fund commercialization or R&D, and can deter large strategic partners that require stronger balance sheet stability.

Kane Biotech News

Kane Biotech’s revyve Wound Gel Gains Peer-Reviewed Validation in International Wound Journal

Kane Biotech ( ($TSE:KNE) ) has shared an announcement. Kane Biotech announced that its revyve antimicrobial wound gel...

3d ago

Kane Biotech’s revyve Wound Gel Gains Peer-Reviewed Validation in International Wound Journal

Kane Biotech ( ($TSE:KNE) ) just unveiled an update. Kane Biotech announced that its revyve Antimicrobial Wound Gel...

3d ago

Kane Biotech Expands U.S. Distribution for revyve Wound Care Line

Kane Biotech ( ($TSE:KNE) ) has shared an update. Kane Biotech has signed non-exclusive U.S. distribution and sales...

4d ago

Kane Biotech Wins FDA Clearance and Expands Quality Certification for revyve Wound Care Line

Kane Biotech ( ($TSE:KNE) ) has shared an announcement. Kane Biotech has secured U.S. FDA 510(k) clearance for...

6d ago

Kane Biotech Restarts North American Sales Push and Bolsters Wound Care Leadership

Kane Biotech ( ($TSE:KNE) ) just unveiled an announcement. Kane Biotech has restarted commercial activities in the United...

11d ago

Kane Biotech Raises $700,000 in Insider-Led Private Placement

Kane Biotech ( ($TSE:KNE) ) has provided an update. Kane Biotech Inc. has closed a non-brokered private placement...

2M ago

Kane Biotech Showcases Advancements in Wound Care at Industry Meeting

Kane Biotech ( ($TSE:KNE) ) has shared an announcement. Kane Biotech presented new clinical data at the Innovations...

2M ago

Kane Biotech’s revyve Wound Gel Spray Gains Health Canada Approval

Kane Biotech ( ($TSE:KNE) ) has provided an announcement. Kane Biotech has announced that its revyve Antimicrobial Wound...

2M ago

Kane Biotech Reports Q3 2025 Results Amid Strategic Progress in Wound Care Market

Kane Biotech ( ($TSE:KNE) ) has provided an announcement. Kane Biotech announced its third quarter 2025 financial results,...

3M ago

Kane Biotech Launches $800,000 Private Placement Offering

Kane Biotech ( ($TSE:KNE) ) has issued an announcement. Kane Biotech Inc. has announced a non-brokered private placement...

3M ago

KNE FAQ

What was Kane Biotech Inc’s price range in the past 12 months?

Kane Biotech Inc lowest stock price was C$0.03 and its highest was C$0.12 in the past 12 months.

What is Kane Biotech Inc’s market cap?

Kane Biotech Inc’s market cap is C$7.26M.

When is Kane Biotech Inc’s upcoming earnings report date?

Kane Biotech Inc’s upcoming earnings report date is Mar 19, 2026 which is in 24 days.

How were Kane Biotech Inc’s earnings last quarter?

Kane Biotech Inc released its earnings results on Nov 28, 2025. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.

Is Kane Biotech Inc overvalued?

According to Wall Street analysts Kane Biotech Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Kane Biotech Inc pay dividends?

Kane Biotech Inc does not currently pay dividends.

What is Kane Biotech Inc’s EPS estimate?

Kane Biotech Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kane Biotech Inc have?

Kane Biotech Inc has 181,596,560 shares outstanding.

What happened to Kane Biotech Inc’s price movement after its last earnings report?

Kane Biotech Inc reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 33.333%.

Which hedge fund is a major shareholder of Kane Biotech Inc?

Currently, no hedge funds are holding shares in TSE:KNE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kane Biotech Inc

Kane Biotech (KNE) is a biotechnology company focused on the development of innovative antimicrobial technologies aimed at addressing biofilm-related challenges across various sectors, including healthcare, veterinary, and industrial applications. The company specializes in creating patented products designed to prevent and treat biofilm infections, which are significant contributors to chronic infections and device-related complications. Kane Biotech's core products include wound care solutions and antimicrobial coatings that enhance the efficacy of medical devices.